In a report released on January 4, Jailendra Singh from Truist Financial maintained a Hold rating on Cano Health (CANO – Research Report). The company’s shares closed last Friday at $3.99.
According to TipRanks, Singh is an analyst with an average return of -15.2% and a 33.54% success rate. Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Evolent Health, and Agilon Health.
Cano Health has an analyst consensus of Moderate Sell, with a price target consensus of $3.75.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $190.00 and a one-year low of $3.60. Currently, Cano Health has an average volume of 272.8K.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CANO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cano Health (CANO) Company Description:
Jaws Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
Read More on CANO:
